{
    "2020-11-19": [
        [
            {
                "time": "2023-11-01",
                "original_text": "Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy",
                "features": {
                    "keywords": [
                        "Novartis",
                        "exclusive rights",
                        "acute respiratory distress syndrome",
                        "cell therapy"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-11-01",
                "original_text": "Price Over Earnings Overview: Novartis",
                "features": {
                    "keywords": [
                        "Price Over Earnings",
                        "Novartis"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance",
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-11-01",
                "original_text": "New data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases",
                "features": {
                    "keywords": [
                        "ASH",
                        "hematology portfolio",
                        "blood cancers",
                        "hematologic diseases",
                        "Novartis"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-11-01",
                "original_text": "Novartis set to achieve 100% renewable electricity in its European operations",
                "features": {
                    "keywords": [
                        "Novartis",
                        "renewable electricity",
                        "European operations"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "energy",
                        "environmental sustainability"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}